HLN Stock Analysis: Haleon | NYSE
Drug Manufacturers - Specialty & Generic | NYSE, USA | Market Cap: 42.217m USD | 12M Return: -5% | US4055521003 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 91.9M
EPS Trend: -2.8%
Qual. Beats: 0
Rev. Trend: 81.6%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 4 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Haleon plc (NYSE: HLN) is a global consumer healthcare company headquartered in Weybridge, United Kingdom, with origins dating back to 1715. The company researches, develops, manufactures, and sells a broad portfolio of over-the-counter (OTC) health products across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. Its offering spans oral health (Sensodyne, Polident, Parodontax, Biotene), vitamins and supplements (Centrum, Emergen-C, Caltrate), respiratory relief (Theraflu, Flonase), pain management (Voltaren, Panadol, Advil), and digestive and allergy products (TUMS, ENO, Fenistil).
The firm was spun off from GlaxoSmithKline and listed on the NYSE in July 2022, originally incorporated as DRVW 2022 plc before adopting the Haleon name. As a pure-play consumer healthcare business, Haleon competes in the global OTC and personal care segment, which is generally characterized by brand-led, consumer-marketed products sold through retail pharmacies, grocery, and e-commerce channels rather than through prescription-based distribution models typical of the broader healthcare industry.
- Sensodyne oral health pricing power drives segment revenue growth
- Post-spin-off debt paydown pace limits buyback and dividend flexibility
- Strong pound translation headwind pressures reported revenue and margin
| Net Income: 1.62b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 1.62 > 1.0 |
| NWC/Revenue: -17.40% < 20% (prev -7.54%; Δ -9.85% < -1%) |
| CFO/TA 0.07 > 3% & CFO 2.39b > Net Income 1.62b |
| Net Debt (7.51b) to EBITDA (2.95b): 2.55 < 3 |
| Current Ratio: 0.69 > 1.5 & < 3 |
| Outstanding Shares: last quarter (4.46b) vs 12m ago -3.21% < -2% |
| Gross Margin: 65.54% > 18% (prev 64.51%; Δ 1.04% > 0.5%) |
| Asset Turnover: 34.76% > 50% (prev 25.83%; Δ 8.93% > 0%) |
| Interest Coverage Ratio: 8.19 > 6 (EBIT TTM 2.60b / Interest Expense TTM 317.1m) |
| A: -0.06 (Total Current Assets 4.27b - Total Current Liabilities 6.21b) / Total Assets 32.4b |
| B: 0.85 (Retained Earnings 27.5b / Total Assets 32.4b) |
| C: 0.08 (EBIT TTM 2.60b / Avg Total Assets 32.1b) |
| D: 1.01 (Book Value of Equity 16.3b / Total Liabilities 16.0b) |
| Altman-Z'' = 3.99 = AA |
| DSRI: 0.80 (Receivables 2.33b/2.14b, Revenue 11.2b/8.22b) |
| GMI: 0.98 (GM 64.51% / 65.54%) |
| AQI: 0.99 (AQ_t 0.81 / AQ_t-1 0.81) |
| SGI: 1.36 (Revenue 11.2b / 8.22b) |
| TATA: -0.02 (NI 1.62b - CFO 2.39b) / TA 32.4b) |
| Beneish M = -2.95 (Cap -4..+1) = A |
As of September 12, 2026, the stock is trading at USD 9.19 with a total of 10,035,729 shares traded. Over the past week, the price has changed by -6.80%, over one month by -6.84%, over three months by +2.44% and over the past year by -5.03%.
Current recommended Stop Loss: 8.90 (which is 3.2% or 1.5 ATR below the current price).
Haleon has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy HLN.
- StrongBuy: 2
- Buy: 2
- Hold: 0
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 12 | 30.5% |
Market Cap GBP = 31.2b (42.2b USD * 0.7396 USD.GBP)
P/E Trailing = 19.5918
P/E Forward = 16.5837
P/S = 3.7856
P/B = 1.9588
P/EG = 2.2715
Revenue TTM = 11.2b GBP
EBIT TTM = 2.60b GBP
EBITDA TTM = 2.95b GBP
Long Term Debt = 7.66b GBP (from longTermDebt, last fiscal year)
Short Term Debt = 1.95b GBP (from shortTermDebt, last quarter)
Debt = 8.34b GBP (from shortLongTermDebtTotal, last quarter) + Leases 133.0m
Net Debt = 7.51b GBP (calculated: Debt 8.34b - CCE 821.0m)
Enterprise Value = 38.7b GBP (31.2b + Debt 8.34b - CCE 821.0m)
Interest Coverage Ratio = 8.19 (Ebit TTM 2.60b / Interest Expense TTM 317.1m)
EV/FCF = 18.91x (Enterprise Value 38.7b / FCF TTM 2.05b)
FCF Yield = 5.29% (FCF TTM 2.05b / Enterprise Value 38.7b)
FCF Margin = 18.36% (FCF TTM 2.05b / Revenue TTM 11.2b)
Net Margin = 14.55% (Net Income TTM 1.62b / Revenue TTM 11.2b)
Gross Margin = 65.54% ((Revenue TTM 11.2b - Cost of Revenue TTM 3.85b) / Revenue TTM)
Gross Margin QoQ = 66.05% (prev 65.03%)
Tobins Q-Ratio = 1.20 (Enterprise Value 38.7b / Total Assets 32.4b)
Interest Expense / Debt = 3.80% (Interest Expense 317.1m / Debt 8.34b)
Taxrate = 23.28% (496.8m / 2.13b)
NOPAT = 1.99b (EBIT 2.60b * (1 - 23.28%))
Current Ratio = 0.69 (Total Current Assets 4.27b / Total Current Liabilities 6.21b)
Debt / Equity = 0.51 (Debt 8.34b / totalStockholderEquity, last quarter 16.3b)
Debt / EBITDA = 2.55 (Net Debt 7.51b / EBITDA 2.95b)
Debt / FCF = 3.67 (Net Debt 7.51b / FCF TTM 2.05b)
Total Stockholder Equity = 16.1b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.06% (Net Income 1.62b / Total Assets 32.4b)
RoE = 10.06% (Net Income TTM 1.62b / Total Stockholder Equity 16.1b)
RoCE = 10.91% (EBIT 2.60b / Capital Employed (Equity 16.1b + L.T.Debt 7.66b))
RoIC = 7.22% (NOPAT 1.99b / Invested Capital 27.6b)
WACC = 4.44% (E(31.2b)/V(39.6b) * Re(4.85%) + D(8.34b)/V(39.6b) * Rd(3.80%) * (1-Tc(0.23)))
Discount Rate = 4.85% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -91.32 | Cagr: -1.53%
[DCF] Terminal Value 77.97% ; FCFF base≈1.83b ; Y1≈2.10b ; Y5≈3.09b
[DCF] Fair Price = 8.85 (EV 46.4b - Net Debt 7.51b = Equity 38.9b / Shares 4.40b; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -2.77 | EPS CAGR: -4.90% | SUE: -0.22 | # QB: 0
Revenue Correlation: 81.58 | Revenue CAGR: 13.80% | SUE: 1.56 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS next Quarter (2026-09-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=0.57 | Chg30d=+1.13% | Revisions=+50% | GrowthEPS=+12.2% | GrowthRev=+3.2%
EPS next Year (2027-12-31): EPS=0.63 | Chg30d=+2.37% | Revisions=+50% | GrowthEPS=+9.5% | GrowthRev=+4.2%
[Analyst] Revisions Ratio: +67% (up=6, down=0)